Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C B Post

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Plos One|February 9, 2026
Study protocol for a multicenter phase II prospective externally controlled non-inferiority trial of hypofractionated re-irradiation in patients with recurrent high-grade glioma (RISinG)A M de Jong, A T J van der Boog, C C B Post, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2026
No prognostic role for FIGO grading in mismatch repair deficient endometrial carcinomaFamke C Wakkerman, Cathalijne C B Post, Gitte Ørtoft, et al.
Journal of the National Cancer Institute|March 11, 2021
Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial CancerCathalijne C B Post, Ellen Stelloo, Vincent T H B M Smit, et al.
Maturitas|December 6, 2025
Age-related differences in patient preferences for adjuvant chemotherapy for high-risk endometrial cancerFamke C Wakkerman, Cathalijne C B Post, Jan Willem M Mens, et al.
Obstetrical & Gynecological Survey|December 30, 2025
Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 TrialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
The Lancet. Oncology|September 8, 2025
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
Journal of Computational Chemistry|May 16, 2009
CHARMM: the biomolecular simulation programB R Brooks, C L Brooks, A D Mackerell, et al.
International Journal of Radiation Oncology, Biology, Physics|November 1, 2020
Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 TrialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Plos One|February 9, 2026
Study protocol for a multicenter phase II prospective externally controlled non-inferiority trial of hypofractionated re-irradiation in patients with recurrent high-grade glioma (RISinG)A M de Jong, A T J van der Boog, C C B Post, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2026
No prognostic role for FIGO grading in mismatch repair deficient endometrial carcinomaFamke C Wakkerman, Cathalijne C B Post, Gitte Ørtoft, et al.
Journal of the National Cancer Institute|March 11, 2021
Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial CancerCathalijne C B Post, Ellen Stelloo, Vincent T H B M Smit, et al.
Maturitas|December 6, 2025
Age-related differences in patient preferences for adjuvant chemotherapy for high-risk endometrial cancerFamke C Wakkerman, Cathalijne C B Post, Jan Willem M Mens, et al.
Obstetrical & Gynecological Survey|December 30, 2025
Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3): 10-Year Clinical Outcomes and Post Hoc Analysis by Molecular Classification From a Randomized Phase 3 TrialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
The Lancet. Oncology|September 8, 2025
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
Journal of Computational Chemistry|May 16, 2009
CHARMM: the biomolecular simulation programB R Brooks, C L Brooks, A D Mackerell, et al.
International Journal of Radiation Oncology, Biology, Physics|November 1, 2020
Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in the Randomized PORTEC-3 TrialCathalijne C B Post, Stephanie M de Boer, Melanie E Powell, et al.
Pageof 5